Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and genetic association studies on susceptibility to the disease are limited. We sought to identify possible overlap of genetic susceptibility loci between pancreatic ductal adenocarcinoma (PDAC) and pNEN; therefore, PDAC susceptibility variants (n=23) from Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 3,277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the odds associated with pNEN risk, disease onset and tumor characteristics. Main effect analyses showed four PDAC susceptibility variants – rs9854771, rs1561927, rs9543325 and rs10919791 to be associated with pNEN risk. Subs...
Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms for which very little is kno...
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers. Its poor prognosis is pred...
Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA,...
Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and ...
Pancreatic ductal adenocarcinoma (PDAC) is a neoplasm characterized by a high mortality rate due to ...
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less...
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less...
Early onset pancreatic cancer (EOPC) is a rare disease with a very high mortality rate. Almost nothi...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Two recent genome-wide association studies (GWAS) of pancreatic ductal adenocarcinoma (PDAC), conduc...
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer (PC). It is a r...
Pancreatic ductal adenocarcinoma (PDAC), which represent the 95% of all the pancreatic cancers, is o...
WOS: 000342079600054PubMed ID: 25213764The diagnosed incidence of pancreatic neuroendocrine tumors (...
Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA,...
Germline genetic variability might contribute, at least partially, to the survival of pancreatic duc...
Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms for which very little is kno...
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers. Its poor prognosis is pred...
Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA,...
Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and ...
Pancreatic ductal adenocarcinoma (PDAC) is a neoplasm characterized by a high mortality rate due to ...
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less...
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less...
Early onset pancreatic cancer (EOPC) is a rare disease with a very high mortality rate. Almost nothi...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Two recent genome-wide association studies (GWAS) of pancreatic ductal adenocarcinoma (PDAC), conduc...
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer (PC). It is a r...
Pancreatic ductal adenocarcinoma (PDAC), which represent the 95% of all the pancreatic cancers, is o...
WOS: 000342079600054PubMed ID: 25213764The diagnosed incidence of pancreatic neuroendocrine tumors (...
Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA,...
Germline genetic variability might contribute, at least partially, to the survival of pancreatic duc...
Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms for which very little is kno...
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers. Its poor prognosis is pred...
Pancreatic cancer is the fourth leading cause of cancer deaths in the European Union and in the USA,...